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To gain insight into the cellular readout of DNA
methylation, we established a strategy for systemat-
ically profiling the genome-wide distribution of chro-
matin-interacting factors. This enabled us to create
genomic maps for the methyl-CpG-binding domain
(MBD) family of proteins, including disease-relevant
mutants, deletions, and isoforms. In vivo binding of
MBD proteins occurs predominantly as a linear func-
tion of local methylation density, requiring functional
MBD domains and methyl-CPGs. This interaction
directs specificity of MBD proteins to methylated,
CpG-dense, and inactive regulatory regions. In
contrast, binding to unmethylated sites varies be-
tween MBD proteins and is mediated via alternative
domains or protein-protein interactions. Such target-
ing is exemplified by NuRD-complex-mediated teth-
ering of MBD2 to a subset of unmethylated, active
regulatory regions. Interestingly, MBD3 also oc-
cupies these sites, but like MBD2, binding is inde-
pendent of the presence of hydroxymethylation.
These functional binding maps reveal methylation-
dependent and -independent binding modes and
revise current models of DNA methylation readout
through MBD proteins.INTRODUCTION
In higher eukaryotes, DNAmethylation is a covalent modification
of cytosine bases associated with transcriptional repression.
Recent advances generated base-pair resolution maps for this
modification in several organisms, including Arabidopsis, hu-
man, and mouse (Cokus et al., 2008; Lister et al., 2009; Stadler
et al., 2011). This unprecedented detail refined our view of the
genomic distribution and dynamic behavior of DNA methylation
and identified features of methylomes. In comparison, our cur-
rent knowledge on how DNA methylation is interpreted and
how it influences genome regulation is incomplete.480 Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc.Based on their ability to bind methylated DNA in vitro, the
family members of methyl-CpG-binding domain (MBD) proteins
are primary candidates for the readout of DNA methylation
(Meehan et al., 1989; Hendrich and Bird, 1998). Protein interac-
tion studies and in vitro experiments have led to amodel in which
MBD1, MBD2, MBD4, and MeCP2 recruit chromatin remodel-
ers, histone deacetylases, and methylases to methylated DNA,
leading to transcriptional repression (Nan et al., 1998; Ng
et al., 1999). Furthermore, alternative functions for MBD proteins
have been proposed in various processes, including transcript
splicing and chromatin compaction, but also gene activation
(Young et al., 2005; Yasui et al., 2007; Chahrour et al., 2008).
MBD3, a component of the nucleosome remodeling and histone
deacetylase (NuRD) complex, is the only member of this family
lacking specificity toward methyl-CpGs in vitro due to mutations
in the MBD domain (Zhang et al., 1999; Saito and Ishikawa,
2002). A recent report suggested, however, that MBD3 binds
5-hydroxymethylcytosine, the product of active demethylation
by the TET family of proteins (Yildirim et al., 2011).
With the exception of MBD3, single deletions ofMbd1,Mbd2,
andMbd4 result in mild developmental phenotypes, suggesting
a redundant function for MBD proteins (Hendrich et al., 2001;
Martı´n Caballero et al., 2009). Mutations in the most-studied
MBD protein, MeCP2, cause a neurological disorder known as
Rett syndrome in females and are lethal in males (Amir et al.,
1999). MeCP2 is highly expressed in the postnatal brain (Skene
et al., 2010), yet transcriptome profiling of MeCP2 null mouse
brains did not reveal a clear picture of direct target genes (Tudor
et al., 2002).
Largely due to lack of specific antibodies suitable for
chromatin immunoprecipitation (ChIP), limited information
exists on the genomic binding of MBD proteins. This, in turn,
hindered our ability to relate in vivo binding behavior with
DNA methylation, chromatin, and gene activity in detail. More-
over, classical ChIP approaches do not provide a direct compar-
ison of protein variants and mutants that would address the
contribution of individual protein domains toward genomic
localization.
To generate functional binding maps for the MBD protein
family, we have devised a system that combines biotin tagging
with controlled and homogenous expression of the protein of
interest through repetitive targeting of the same genomic site.
Importantly, this set-up provides a platform to investigate the
functional requirement of protein domains and even single amino
acid residues for binding to chromatin in vivo. With this
approach, we have generated 29 different genome-wide profiles
of MBD proteins and their corresponding isoforms or disease
related mutants in mouse embryonic stem (ES) cells and derived
somatic cell types. This data set enabled us to contrast the bind-
ing logics of different MBD proteins and relate them to base-pair
resolution DNA methylomes, the presence of 5-hydroxymethyl-
cytosine, and distinct histonemodifications. Our analysis reveals
qualitatively and quantitatively that the majority of binding that is
observed for wild-type MBD1, MBD2, MBD4, and MeCP2 is
directed toward methylated regions of the genome. This occurs
in a direct and linear dependency on the local density of methyl-
ated CpGs, regardless of underlying genomic features. Impor-
tantly, methylation-dependent MBD protein enrichment at
promoters coincides with repression of the linked gene. Muta-
tions within MBD domains lead to loss of binding specificity to
methylated sites, similar to that observed for wild-type proteins
in ES cells lacking DNA methylation. These mutant binding pro-
files further unmask DNA-methylation-independent target sites,
which largely differ between MBD family members and rely on
their domain composition.
Taken together, these functional bindingmaps reveal complex
binding modes for this protein family and revise current models
of gene repression through MBD proteins.
RESULTS
Combined Genomic Targeting and Biotin Tagging
for Iterative Binding Analysis of Chromatin and DNA
Interacting Factors
To monitor genomic binding for the MBD protein family and
selected variants, we employed a recombinase-mediated,
genomic targeting approach to ensure controlled and homoge-
nous expression of biotin-tagged proteins of interest from a
single defined genomic site. This allows stringent streptavidin-
based immunoprecipitation of the biotin-tagged factors in
mouse ES and derived neuronal cells (Figure 1A and Figures
S1A–S1E).
Next, we separately inserted expression cassettes for all
members of the MBD protein family (Figure 1B) and monitored
expression levels by comparing wild-type and biotin-tagged
cell lines (Figures 1C, S1F, and S1G). Purification of biotin-
tagged MBD proteins isolated established cofactors, which
validated correct interactions with binding partners such as
the NuRD complex (Figures 1C and S1H), (Ng et al., 1999;
Zhang et al., 1999). These interactions were further confirmed
in differentiated neurons and by complex purifications utilizing
antibodies raised against members of the NuRD complex (Fig-
ures S1I–S1M). We further verified nuclear localization for all
tagged MBD domain proteins in stem cells and differentiated
neurons (Figures 1D and 1E) (Lewis et al., 1992; Hendrich and
Bird, 1998).
We conclude that tagged MBD domain proteins that are ex-
pressed as single-copy transgenes from the same ectopic site
show nuclear localization and protein complex interactions
similar to that of the endogenous proteins.Genomic Mapping in Pluripotent and Somatic Cells
Reveals Conserved Binding of MBD Proteins to Densely
Methylated Regions
To identify genomic binding sites, we performed ChIP with
biotin-tagged MBD proteins in mouse ES cells followed by
high-throughput sequencing. Visual inspection of resulting
MBD1, MBD2, MBD4, and MeCP2 binding profiles illustrated
peaks at regions of dense DNA methylation such as methylated
CpG islands, which we further verified by quantitative PCR (Fig-
ures 2A and S2A). This result is in line with binding of MBD pro-
teins tomethylated DNA in vitro (Lewis et al., 1992; Hendrich and
Bird, 1998). In contrast, MBD3 shows no visible enrichment at
methylated islands, in accordance with in vitro studies reporting
that its MBD domain is mutated and unable to bind methylated
DNA (Saito and Ishikawa, 2002).
Given that somatic differentiation entails expression changes
of endogenous MBD proteins (Figures S2B and S2C), we next
asked whether binding to methylated CpG islands is conserved
upon loss of pluripotency and commitment to a somatic cell fate.
To address this question, we profiled genome-wideMBD protein
binding in neuronal cells derived from ES cells carrying biotin-
tagged MBD proteins. Binding profiles at methylated CpG
islands show identical enrichments between ES and neuronal
cells, compatible with the lack of methylation changes at these
sites (Figure S2D) (Mohn et al., 2008).
To quantify the relationship between DNA methylation and
MBD protein binding, we took advantage of single base-pair
DNA methylation maps that we recently generated in the iden-
tical mouse ES cell clone and derived neuronal cells (Stadler
et al., 2011). We calculated the percentage of methylation for in-
dividual CpGs and the actual methylation density for a genomic
region by combiningmethylation percentages with the density of
CpG dinucleotides (Figure 2B). The resulting methylation density
reflects the local concentration of methylated CpGs as the bona
fide substrate for proteins that bind methylated DNA (Figure 2C).
Regions enriched for MBD proteins show irregular shape and
length, creating a binding pattern that is incompatible with con-
ventional peak calling methods (Figures 2A and S2D). Thus, to
comprehend the relationship between MBD protein enrichment
and methylation properties, we binned the genome into 1-kilo-
base-sized windows and then selected the highest- and
lowest-ranked windows based on MBD protein enrichment for
further analysis (see Experimental Procedures). This revealed
that all MBD proteins, except MBD3, preferentially bind methyl-
ated CpG-rich sequences. CpG-poor regions are weakly bound
even when methylated, indicating that methylation density is a
key determinant for genome-wide recruitment (Figures 2D and
S2E). This becomes evident when MBD protein enrichment for
the entire data set is ranked by DNA methylation density and
vice versa (Figures 2E and S2F). Dependency on methylation
density is further illustrated by comparing methylated and unme-
thylated CpG islands of similar CpG density (Figure S2G).
Surprisingly, MBD2 and MBD4 show a notable binding at unme-
thylated CpG islands, a finding that we explore with functional
mutants further below. Importantly, binding to methylated
islands is conserved between MBD1, MBD2, MBD4, and
MeCP2, but not MBD3, implicating a functional MBD domain
as a critical factor in localization (Figure 2D). In line with thisCell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc. 481
Figure 1. Controlled Expression Combined with Biotin Tagging for Functional Analysis of MBD Proteins
(A) Principle of iterative location analysis using recombinase-assisted mapping of biotinylated proteins (RAMBiO). Biotin-tagged MBD protein (MBP) cDNAs are
targeted to a defined genomic site of the mouse ES cell genome via recombinase mediated cassette exchange (RMCE). Stable Bir-A expression leads to
biotinylation of introduced proteins for subsequent chromatin immunoprecipitation (IP) with streptavidin and sequencing of eluted DNA. Reintroduction of
mutated proteins to the same genomic location enables direct comparisons, whereas in vitro differentiation enables binding analysis in differentiated cells.
(B) Scheme of MBD family of proteins with known DNA and protein interaction domains (MBD, methyl-CpG-binding domain; TRD, transcriptional repression
domain; CXXC, ZnF Cys-x-x-Cys domain; CC, coiled-coil; G/R, arginine-rich).
(C) Immunoprecipitation (IP) of biotin-tagged MBD2 efficiently copurifies NuRD complex members (HDAC1). Equivalent amounts of nuclear extracts were used
for input (in) and IP.
(D) Localization analysis of biotin-tagged MBD proteins in ESC nuclei using streptavidin staining. DAPI staining reveals chromocenters.
(E) Nuclear localization analysis comparing biotin-tagged and endogenous MeCP2 in ES-cell-derived postmitotic neurons using either streptavidin or antibodies
against MeCP2. Neurons derived from empty Bir-A ES cells were used to visualize endogenous MeCP2 staining.
See also Figure S1.observation, bound regions are shared between pluripotent and
differentiated cells, and binding is thus conserved between cell
types (Figures S2H and S2I).
To test whether protein interactions and genomic binding
depend on expression levels, we expressed biotin-tagged
MBD2 andMeCP2 from the same genomic locus but under con-
trol of the weaker CMV promoter, which leads to 6-fold reduced
expression and decreased protein levels. Though this reduces
the overall strength of the signal as expected, we nevertheless
detect similar interactions and genomic binding, indicating that
binding behavior of MBD proteins is largely independent of
abundance (Figures S2J and S2K).
De novo methylation during differentiation occurs mostly at
CpG-poor regions, therefore resulting in limited increase of local482 Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc.methylation density (Figure S2L) (Mohn et al., 2008; Stadler et al.,
2011). However, we observe that CpG-dense regions gaining
methylation upon differentiation show coinciding increase in
MBD protein binding. This is, for example, the case for a somatic
DMR at the Gnas-imprinted gene cluster or at CpG island
borders (Figures 2F and 2G). These borders attract methylation
during differentiation even though the island itself remains
unmethylated (Figures S2M and S2N).
DNA Methylation Density Is the Major Determinant
of MBD Protein Enrichment Relative to Functional
Elements and Chromatin Components
Next, we compared MBD protein enrichment to methylation
density at the level of the genome. Strikingly, enrichment for
Figure 2. MBD Proteins Are Targeted to
Regions with High Methylation Density in
ES and Somatic Cells
(A) MBD protein localization at example chromo-
somal regions. Shown is the enrichment for all five
MBD proteins at the Peg10 and the Xist promoter,
which both harbor a methylated CpG island
(marked as a green bar above the gene profile).
The differentially methylated region (DMR) of
Peg10 is indicated as a black line. (Top track) CpG
density per 100 bp is shown in gray and methyl-
ation percentage of single CpGs (% m-CpG) as
red dots. MBD protein enrichment is calculated as
library-normalized number of tags per 100 bp.
(B) Illustration of the relation between methylation
percentage, CpG density, and methylation density
and (C) exemplified for the promoter of the sperm-
specific Dazl gene. CpGs % and CpG density are
represented as in (A), and the red line denotes DNA
methylation density per 100 bp (m-CpG density) at
the displayed region. Green bar represents a CpG
island within the Dazl promoter.
(D) Comparison of DNA methylation, CpG density
per 100 bp, and methylation density per 100 bp at
regions enriched and depleted for MBD protein
binding (top). Regions were identified as a set of
1-kb-sized windows displaying highest and lowest
MBD protein enrichment scores in the entire
genome. A set of randomly selected windows is
shown for comparison. Binding conservation be-
tween MBD proteins at enriched and depleted
regions is shown (bottom).
(E) Whole-genome representation of MBD protein
enrichment at 1-kb-sized windows ranked by
increasing methylation density, showing that both
positively correlate throughout the entire genome.
(F) Browser snapshot showing neuronal progenitor
cell (NPC)-specific gain of MBD2 binding at a
somatic DMR within the Gnas/Nespas-imprinted
cluster. (Top track) CpG density (gray), m-CpG
density in ESC (red line), and NPC (blue line).
(G) Average density plot showing gain in DNA
methylation density at CpG island borders during
neuronal differentiation (dashed line), which
coincideswith increased recruitment ofMBD1 and
MeCP2 during differentiation. This dynamic in-
crease is not detectable for MBD2 and MBD4,
which is a consequence of their intrinsic affinity to
unmethylated islands in ES cells. Shown are log2
fold changes in MBD protein enrichment between
ES and derived neuronal cells. CGi, unmethylated
CpG islands.
See also Figure S2.
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MBD1, MBD2, MBD4, and MeCP2 increases linearly with
methylation density in the same cellular and genomic context
(Figures 3A and S3A). Moreover, binding does not appear to
plateau with increased local concentration of methylated
cytosines. Thus, MBD protein enrichment to chromatin appears
primarily as a linear function of local methylation density.
This quantitative relation enables prediction of MBD protein
binding to genomic elements based on methylation density
alone. We first analyzed promoters, exons, introns, and repeti-
tive elements with varying levels of DNA methylation and CpG
density (Figure 3B). Average methylation density is highest for
exons and lowest for CpG-rich promoters (HCP), as expected.
Repeats, introns, intermediate (ICP), and low-CpG promoters
(LCP) show similar average methylation densities though with
qualitative differences (Figure 3B). At repeats, introns, and
LCPs, methylation percentage is high and CpG density is low
throughout the majority of elements. However, within ICPs,
methylation and CpG density are highly variable, as reported
previously (Weber et al., 2007) (Figures S3H and S3I). Global
analysis across all elements revealed that binding of MBD
proteins is more frequent at exons and a subset of promoters
while less frequent at repetitive DNA. Enrichment at exons is
compatible with general elevated methylation density at the
majority of coding sequences but appears independent of tran-
scriptional activity (Figures 3C and S3B–S3E). For the remaining
genomic sites, we could predict MBD protein binding behavior
primarily through binning based on local methylation density.
This is the case for repetitive elements that are typically low in
CpG density while highly methylated. Only a few notable excep-
tions that have retained higher CpGdensity—mostly members of
the endogenous retrovirus family, such as intracisternal A parti-
cles (IAP)—display higher methylation densities concomitant
with higher frequency of MBD protein occupancy (Figures 3D,
S3F, and S3G and Table S2).
At gene promoters, increased binding is most notable at pro-
moters with intermediate CpG content (ICP) for all MBD proteins
(Figure 3B and Table S1). A subset of ICP promoters is methyl-
ated, and indeed, MBD binding occurs to this group. (Figures
3E, S3H, and S3I). Low CpG content (LCP) promoters, however,
show only negligible enrichment for MBD proteins despite being
methylated, likely due to their low CpG density (Figure 3B).
Despite the absence of DNA methylation, we observed again a
notable binding of MBD2 and MBD4 at high CpG content
(HCP) and unmethylated ICP promoters, similar to the binding
preferences of MBD3 (Figures 3B and 3E). Notably, ranking pro-
moters bymethylation density results in contrastingMBDprotein
and RNA polymerase II enrichments, linking MBD protein abun-
dance to gene regulation in vivo (Figures 3F and S3J).
To relate MBD binding to other chromatin components,
histone marks, and transcription factors, we calculated a corre-
lation matrix using ES cell data sets from various sources
(Figure 3G). Unsupervised clustering of this matrix identified
two major groups. One consists mostly of histone marks and
features associated with active chromatin, such as methylation
of lysine 4 on histone H3, P300 occupancy, and DNaseI hyper-
sensitivity (DHS)—a measure of transcription factor binding to
regulatory regions (Dunham et al., 2012). The second group is
represented by increased methylation density and consequently484 Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc.MBD1, MBD2, MBD4, and MeCP2 enrichment. Interestingly, we
also observed that MBD protein localization also correlates with
active chromatin marks and 5-hydroxymethylcytosine (5hmC)
(Figure 3G).
To detect the presence of additional binding cues otherwise
masked by the strong dependency on methylation density, we
normalized MBD1, MBD2, MBD4, and MeCP2 enrichments to
methylation density by applying a linear model (see Experimental
Procedures). This allowed us to estimate the contribution of
sequence or chromatin composition around methylated CpGs.
However, throughout all analyzed factors, including inter-CpG
distance and enriched sequence motifs, only DHS, activating
histone marks (H3K4me1 and H3K27ac), and 5hmC showed
minor correlations with a subset of MBD proteins (Figures S3K
and S3L). Though not deterministic for general binding behavior,
this correlation is in agreement with the recruitment of MBD2
and MBD4 to unmethylated promoters and active chromatin
marks, which we noted above (Figures 3B and 3G).
Recent reports have implicated 5-hydroxymethylcytosine as
an alternative cue for the recruitment of MBD3 and MeCP2
(Yildirim et al., 2011; Melle´n et al., 2012), whereas other contra-
dicting studies report no evidence for recognition of 5hmC
in vitro (Jin et al., 2010; Frauer et al., 2011; Hashimoto et al.,
2012; Spruijt et al., 2013). Importantly, genome-wide 5hmC
abundance increases with higher methylation density, making
it difficult to distinguish 5mC from 5hmC binding in vivo (Fig-
ure S3M). Thus, the observed general correlations of MBD1,
MBD2, MBD4, and MeCP2 with 5hmC could simply reflect bind-
ing to 5-methylcytosine (Figure 3G). Regulatory elements are the
only reported incidence in which 5hmC is abundant at sites of
reduced methylation (Pastor et al., 2011; Stadler et al., 2011).
MBD3 shows increased binding to a subset of these sites, raising
the possibility that 5hmC is involved in recruitment (Figure S3N).
This model has been proposed for MBD3, and it will be
addressed further below (Yildirim et al., 2011).
Together, these data suggest that additional cues from
chromatin modifications or sequence composition are minor
and do not influence preference of MBD proteins to methylated
sites, whereas additional targeting to unmethylated sites was
detected for a subset of MBD proteins.
Functional MBD Domains Are Required for Targeting
to Methylation-Dense Regions In Vivo
To test the dependency on methylation recognition, we profiled
a set of protein variants with mutated MBD domains. In the case
of MeCP2, these include two prominent mutations occurring in
patients with Rett syndrome (R106W and R133C) (Amir et al.,
1999). In addition, we introduced amino acid substitutions at
conserved residues of the MBD domains from MBD1 (R22C),
MBD2 (R181C), and MBD4 (R106C). These mutations have pre-
viously been shown to disrupt specificity toward methylated
DNA (Free et al., 2001; Ohki et al., 2001; Scarsdale et al., 2011)
(Figure S4A). Similar to their wild-type counterparts, we
inserted the tagged variants into the same genomic site
and under the control of the same promoter. Importantly, this
ensured that the introduced protein variations are the only exper-
imental difference. We further verified protein integrity and inter-
actions for these variants (Figure S4B).
Figure 3. MBD Proteins Discriminate Regions by Methylation Density
(A) MBD protein enrichment as a function of methylation density reveals a linear relationship to local concentration of methylated cytosines. Shown are trend lines
calculated by locally weighted polynomial regression (loess curves) on 1-kb-sized windows over chromosome 19.
(B) Average values for DNA methylation, CpG density, methylation density, and MBD protein enrichments at functionally defined genomic elements.
(C) Box plots summarizing MBD protein enrichments at nontranscribed versus highly expressed exons or (D) two families of LTR elements with contrasting
methylation densities. Shown are box plots denoting the interquartile range as a box (IQR) and the lowest and highest values within the range of 1.53 IQR around
the box as whiskers.
(E) Average density plots centered at the transcriptional start sites (TSS) of ICP promoters showing methylation density and MBD protein enrichments for high
(continuous line) and low methylation-dense (dashed line) ICPs. To obtain these bins, we ranked ICPs based on methylation density and selected first and fourth
quartiles.
(F) DNA methylation density separates MBD protein-bound and RNA-Pol-II-bound promoters. Shown are enrichments over background (log2) at promoters
ranked by increasing m-CpG density. Promoters are defined as ± 500 bp around the TSS.
(G) Unsupervised clustering of correlation coefficients between 25 data sets calculated on 1 kb sliding windows over chromosome 19. Note the two distinct
groups that separate active from repressive marks and factors highlighted in blue and red, respectively.
See also Figure S3 and Tables S1 and S2.
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Figure 4. MBD Domain-Methyl-CpG Interactions Are Required for the Majority of Genomic Targets
(A) Nuclear localization of wild-type versus mutant biotin-tagged MBD proteins.
(B) Example genomic regions indicating loss of binding at methylated CpG islands for MBD protein mutants. MBD protein enrichment tracks represent log2 fold
changes between mutant and wild-type forms.
(C) Average enrichment densities at methylated CpG islands illustrating differential binding of wild-type and mutant MBD proteins.
(D) Differences between wild-type and mutated MBD proteins in their ability to bind to methylation-dense regions on chromosome 19. Shown are loess curves of
log2 fold changes of mutant over wild-type.
(E) Nuclear localization of wild-type MBD proteins in Dnmt1, Dnmt3a, and Dnmt3b triple knockout (TKO) ES cells.
(F) Example chromosomal regions indicating loss of binding in TKO cells at CpG islands methylated in wild-type ES cells. Log2 fold changes between TKO and
wild-type ESC samples are shown.
(G) Average enrichment densities in wild-type ES cells and TKO cells over CpG islands that are methylated in wild-type ESC.
(H) Lack of binding in TKO cells at regions with high methylation density in wild-type ESC (shown as loess curves calculated from log2 fold changes between TKO
and wild-type ESC).
See also Figure S4.With the exception of the MeCP2 variant R133C, nuclear
localization analysis of MBD mutants reveals loss of staining
to DAPI-dense chromocenters (Figure 4A). The R133C variant
has previously been suggested to localize to chromocenters
as a result of remaining methyl-CpG affinity and/or longer resi-
dence time on chromatin (Free et al., 2001; Schmiedeberg486 Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc.et al., 2009). Yet whether this localization is linked to DNA
methylation remained unknown. Chromatin immunoprecipita-
tion sequencing for all MBD mutant proteins reveal a loss of
preferential localization to densely methylated regions, as is
evident from representative methylated CpG islands (Figures
4B and S4C). To obtain a comprehensive view on binding to
Figure 5. Additional Binding Preferences
Exposed by Functional Binding Analysis
(A) MeCP2 binds to open chromatin sites in
the absence of DNA methylation. Shown are
average values for DNA methylation, CpG density,
methylation density, and histone modifications in
wild-type ES cells at sites enriched by MeCP2 in
wild-type versus TKO ES cells.
(B) Representative examples for MeCP2 binding in
wild-type and TKO cells contrasted to DNaseI
hypersensitivity (DHS) maps. Arrows highlight
sites with increased MeCP2 binding at DHS in the
absence of DNA methylation. Tracks represent
library-normalized tag counts per 100 bp.
(C) Genomic relocation of MeCP2 in absence of
DNA methylation. Shown are enrichments of
bound sites in the illustrated genomic regions
relative to input.
(D) Representative example for MBD1 binding to
unmethylated CpG islands in the absence of the
MBDdomain (DMBD). (Top track) m-CpG%,CpG,
and m-CpG density as depicted in Figure 2B;
(bottom track) histone H3, lysine-4-dimethyl.
See also Figure S5.methylated CpG islands, we extended our analysis to all
methylated CpG islands in the ES cell genome. This analysis
revealed that binding to these sites was abolished in the pres-
ence of point mutations (Figure 4C). On a more global scale,
our calculations show that the strong positive correlation
between DNA methylation density and binding is largely lost
in these mutants, suggesting that genomic binding to methyl-
ated regions relies on a functional MBD domain (Figures 4D
and S4D).
DNA Methylation Is Required for Targeting MBD
Proteins to CpG-Dense Chromatin
So far, our results let us hypothesize that DNA methylation
density is the main determinant of MBD domain protein target-
ing. To directly test this, we determined protein binding in cells
that lack DNA methylation. We introduced biotin-tagged MBD
proteins into Bir-A-positive, Dnmt1, Dnmt3a, and Dnmt3b tri-
ple-knockout (TKO) ES cells (Tsumura et al., 2006). TKO cells
are depleted of 5-methylcytosine as well as 5-hydroxymethylcy-
tosine, as measured by liquid chromatography and subsequent
mass spectrometry (Figure S4E) and in line with previous reports
(Tsumura et al., 2006; Williams et al., 2011). Immunofluores-
cence experiments show that, although MBD1, MBD2, and
MBD4 no longer localize to DAPI-dense chromocenters,
MeCP2 retains a similar staining to that observed in wild-type
ES cells (Figure 4E).
Binding analysis at representative sites and average profiles at
CpG islands methylated in wild-type ES cells revealed lack of
enrichment for all analyzed MBD proteins in the TKO back-
ground. This argues that DNA methylation is a prerequisite for
MBD protein binding at these sites (Figures 4F, 4G, and S4C).
Similar observations were made at the genome level, whereenrichment at regions with high methyl-CpG content in wild-
type ES cells is lost in TKO (Figures 4H and S4F).
MeCP2 Binding Modes to Chromatin in the Absence
of DNA Methylation
The fact that MeCP2 remains localized at chromocenters in TKO
cells suggests that its localization is, in part, directed by methyl-
CpG-independent binding to chromatin. Indeed, the affinity of
MeCP2 for chromatin and the relative amount of DNA precipi-
tated by MeCP2 does not differ significantly between wild-type
ES and TKO cells and is, in general, three times greater than
for other MBD proteins (Figures S5A and S5B). In contrast, the
amount of precipitated DNA is significantly reduced for MBD1
in TKO compared to wild-type ES cells (Figures S5A and
S5B). Together, these results imply that the general affinity of
MeCP2 to chromatin does not completely rely on specificity
toward DNA methylation (Skene et al., 2010). To gain further
insight into DNA-methylation-independent MeCP2 binding, we
analyzed how lack of DNA methylation affects genomic binding.
Direct comparison of all MeCP2 data sets, including one previ-
ously obtained from adult mouse neurons (Skene et al., 2010),
again highlights that recognition of DNA methylation by a func-
tional MBD domain is the main contributor to binding at specific
genomic sites, regardless of tissue type or expression level (Fig-
ure S5C). Despite loss of binding to methylation-dense regions,
further analysis of MeCP2 recruitment in TKO cells reveals
redistribution to regions with increased DNaseI hypersensitivity,
histone H3K4me1 marks, and H3K27ac marks (Figures 5A–5C
and S5D). This preference for open accessible chromatin is
only unmasked in the absence of genomic DNA methylation
and is in stark contrast to MBD1, where binding is generally
lost in TKO cells (Figure S5D).Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc. 487
Having established the contribution of the MBD domain
and DNA methylation for targeting, we next explored whether
additional domains affect the genome-wide binding preference
of MBD proteins.
A CXXC Domain within MBD1 Mediates Binding to
Unmethylated CpGs in the Absence of the MBD Domain
MBD1 contains three CXXC domains that have been implicated
inmediating binding to unmethylated CpGs (Figures 1B and S5E)
(Jørgensen et al., 2004). Nevertheless, we did not observeMBD1
binding to unmethylated CpG islands despite the presence of a
third CXXC domain (CXXC-3) with strong homology to the CXXC
domains of Cfp1 and MLL (Figure S5F). Strikingly, this was also
observed in the R22C mutant that inactivates the MBD domain
and for thewild-type protein in the TKObackground (Figure S5F),
a finding that disagrees with a previous report in mouse fibro-
blasts (Jørgensen et al., 2004). Surprisingly, however, deletion
of the entire MBD domain results in a strong affinity of the result-
ing variant toward unmethylated CpG islands aswell as concom-
itant loss of binding to methylated CpG islands (Figures 5D and
S5F). A similar preference was also observed for an MBD1 iso-
form (MBD1b) lacking CXXC-3 yet with limited enrichment.
This supports the notion that the remaining CXXC domains
have less affinity toward unmethylated CpGs (Jørgensen et al.,
2004), whereas CXXC-3 dominates binding only in the absence
of the MBD domain (Figures S5E–S5G).
MBD2 Binding to Unmethylated DNA Requires
Interactions with the NuRD Complex
The transcriptional repression domain (TRD) of methyl-CpG-
binding proteins is thought to mediate interaction with binding
partners and induce transcriptional silencing (Nan et al., 1997;
Boeke et al., 2000; Sarraf and Stancheva, 2004). To investigate
how such protein interactions could influence MBD protein
targeting, we removed the respective domains in MBD1 and
MeCP2 and determined genome-wide binding. These experi-
ments revealed no difference in binding when compared to the
full-length proteins, implying that, for MBD1 and MeCP2, the
protein interaction domain does not contribute to chromosomal
recruitment (Figures S6A to S6E).
In the case of MBD2, removal of the TRD domain would also
disrupt the MBD domain (Boeke et al., 2000). Instead, we
focused on the testis-specific MBD2t isoform, which lacks the
C terminus (Figure S6A) (Hendrich and Bird, 1998). Importantly
we show by immunoprecipitation that this isoform does not
interact with NuRD components such as Mi2-beta, HDAC1,
and HDAC2 (Figure 6A). The genome-wide location of MBD2t
to methylated DNA is similar to full-length MBD2 (Figures 6B
and S6B–S6E). Importantly, however, and in contrast to
MBD2t, full-length MBD2 binds in addition to a subset of unme-
thylated sites (Figures 6B–6D and S6F). This suggests that pro-
tein interaction with the NuRD complex is required for binding
of MBD2 to a subset of unmethylated regions. That this recruit-
ment does not involve DNA methylation is further supported by
the fact that these sites are still occupied by the MBD2 R108C
mutant in wild-type ES cells and by wild-type MBD2 in TKO cells
(Figures 6D to 6F). Interestingly, these methylation-independent
sites are DNaseI hypersensitive (DHS) (Figures 6D, 6E, and S6F).488 Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc.They are also low in CpG density and DNA methylation but
enriched for H3K4me1 andH3K27ac and thus show all hallmarks
of active regulatory regions (Figure 6E) (Heintzman et al., 2009;
Stadler et al., 2011). Further examination of MBD2 enrichment
at regulatory regions identified methylation-independent binding
at active promoters and enhancer elements (Figures S6G andH).
Methylation-independent MBD2 sites further coincide with
binding of Mi2-beta and MDB3 in ES cells suggesting a NuRD
complex mediated recruitment (Figures 6D and 6F and Figures
S6G and H). Importantly, we do not observe localization of
NuRD complex members other than MBD2 to methylated sites.
This contradicts with current models of MBD2-mediated target-
ing of NuRD to methylated sites (Figures 6D, S6G and H). We
further noted that MBD3 displays preference to regions sensitive
to DNaseI and positive for H3K4me1 and H3K27ac, comparable
to the methylation-independent binding sites of MBD2, suggest-
ing a similar recruitment as part of NuRD (Figures 6D–6F, S6G,
and S6H).
MBD3 has recently been suggested to bind 5hmC and recruit
the NuRD complex to these sites (Yildirim et al., 2011). Sites pref-
erentially co-occupied by MBD2, MBD3, and NuRD in a methyl-
ation-independent manner are indeed 5hmC and TET1 positive
(Figures 7A, S7A, and S7B). Importantly however, both MBD2
and MBD3 are still present at the same regions in TKO cells,
and binding is thus independent of the presence of 5-methylcy-
tosine and 5-hydroxymethylcytosine (Figures 7A and S7D). This
functional test argues against a recruitment of NuRD through
binding of MBD3 to 5-hydroxymethylcytosine.
Importantly this methylation-independent recruitment of both
MBD2 and MBD3 is largely cell type specific, as most binding
events occur at tissue-specific regulatory regions (Figure 7B)
(Stadler et al., 2011). One potential interpretation of this result
is that MBD2 and MBD3 are binding to a subset of regulatory
regions as part of NuRD in a tissue-specificmanner. This methyl-
ation-independent recruitment accounts for almost all MBD3-
binding events and for a subset of MBD2-binding events that
occur in wild-type cells.
DISCUSSION
The applied approach of controlled expression of tagged pro-
teins via recombinase-based targeting into the same genomic
site enabled rigid comparisons between members and variants
of a protein family implied in binding methylated DNA. This
allowed quantifying and functionally testing the contribution of
individual domains and amino acid residues to genomic target-
ing of MBD proteins in vivo. Furthermore, this strategy is readily
applicable to any chromatin- or DNA-binding factors of interest
in pluripotent and derived somatic cells.
Our comprehensive binding study for MBD1, MBD2, MBD3,
MBD4, and MeCP2 illustrate that, with the exception of MBD3,
DNA methylation is the primary determinant of genomic binding
for all proteins with a functional MBD domain. Qualitatively, this
DNA methylation dependence is in line with the reported in vitro
specificity for MBD domain proteins (Meehan et al., 1989; Hen-
drich and Bird, 1998) and argues that this interaction also ex-
plains many, but not all, in vivo binding events. Combining global
MBD protein binding profiles with base-pair resolution
Figure 6. The C-Terminal Protein-Protein
Interaction Domain Is Required for Methyl-
CpG-Independent Binding of MBD2 to
Active Regulatory Regions
(A) MBD2t does not interact with NuRD compo-
nents in ES cell nuclear extracts. LaminB1 was
used as loading control on 10% of the unbound
fraction (unb.).
(B) Lack of NuRD-interacting domains in MBD2t
results in loss of binding to unmethylated pro-
moters. Shown are average density plots centered
at the TSS of ICP promoters binned by high or low
methylation density (continuous and dashed lines,
respectively).
(C) 2D density plots showing different and con-
served binding between MBD2t and full-length
MBD2 at regions of low (1) and high (2) methylation
density.
(D) Example regions illustrating the dual binding
mode of MBD2 at regions of low (1) or high (2)
methylation density. (Top track) m-CpG %, CpG
density, and m-CpG density as in Figure 2B. ChIP
and DHS tracks represent library-normalized tag
counts per 100 bp.
(E) Properties of methylation-independent binding
sites of MBD2 and MBD3. Shown are average
m-CpG %, CpG density, m-CpG density, DHS,
and histone modifications of enriched regions in
the indicated samples.
(F) Unsupervised clustering of correlation
coefficients showing methyl-CpG-dependent
and -independent binding of MBD2 and correla-
tion to NuRD complex components (Mi2-b and
MBD3). Correlations were calculated using 1 kb
windows (sliding by 100 bp) over chromosome 19.
See also Figure S6.methylomes (Stadler et al., 2011) enabled us to directly quantify
the relation between recruitment and local concentration of
methylated cytosines. This identified a linear relationship
between MBD protein enrichment and local methylation density
for MBD1, MBD2, MBD4, and MeCP2. Furthermore, it enables
us to predict MBD protein binding to genomic elements in ES
cells and to identify dynamic changes in binding during cellular
differentiation, based solely on measuring methylation density.
By modeling the binding data to methylation density, we could
further exclude additional binding cues from chromatin modifi-
cations or sequence composition, arguing against their contribu-
tion to MBD domain specificity in vivo. The linear dependency is
conserved between proteins with functional MBD domains and
between cell types, further arguing that it is an intrinsic behaviorCell 153, 480–4of MBD domains. Further direct evidence
for this model comes from our studies of
mutations in the MBD domain (Amir
et al., 1999; Free et al., 2001), which in
all cases abolish this dependency, remi-
niscent of wild-type protein binding in
cells that lack DNA methylation.
Our findings support the concept that
MBD proteins play a central role in the
cellular readout of DNA methylation. Ourfinding of a strong negative correlation between MBD binding
and promoter activity as well as enhancer accessibility directly
supports a role for MBD proteins in DNA methylation-mediated
genome regulation. However, while the exact molecular mecha-
nism that translates DNA methylation into transcriptional regula-
tion still needs to be deciphered, the linear relationship between
MBD protein recruitment and methylation density is compatible
with the finding that cytosine methylation at regions with high
CpG content, such as CpG islands, leads to stronger repression
than does methylation of CpG-poor sequences (Boyes and
Bird, 1992; Nan et al., 1997). The similar recruitment of different
MBD proteins to methylated DNA is further in line with the
concept of largely redundant function between MBD proteins
in interpreting DNA methylation. This has been proposed as an92, April 11, 2013 ª2013 Elsevier Inc. 489
Figure 7. Tissue-Specific Binding of MBD2 and MBD3 Is Indepen-
dent of 5-Methylcytosine and 5-Hydroxymethylcytosine
(A) Average density profiles centered at regulatory regions defined by low
methylation states in ES cells (LMRs; Stadler et al., 2011) show similar binding
of MBD2 and MBD3 in wild-type and TKO cells, suggesting methylcytosine-
and hydroxymethylcytosine-independent binding. Lack of MBD2t binding
suggests a NuRD-complex-mediated localization of MBD2 to these sites.
(B) MBD2 and MBD3 binding to distal regulatory regions is tissue specific and
methylation independent. Shown are average density profiles for DNA
methylation and corresponding MBD2 and MBD3 enrichments centered at
LMRs specific for ES cells, NPC cells, or both.explanation for the modest phenotypes observed in knockout
mice (Martı´n Caballero et al., 2009).
Importantly, the genomic binding maps of mutated MBD
domain proteins expose additional preferences to a subset of
sites that are DNA methylation independent and that differ
between MBD proteins.
In the case of MBD2, we observed binding to sites that display
DNaseI hypersensitivity and harbor active chromatin marks.
Domain deletions in MBD2 argue that recruitment to these sites
is likely mediated by interaction with NuRD complex members.
Though this supports the observation that MBD2 is part of a
particular NuRD complex (MeCP1, MBD2-NuRD), it challenges
the model that MBD2 recruits this complex to methylated re-
gions in vivo (Ng et al., 1999; Zhang et al., 1999). This is further
supported by the absence of other NuRD complex members—
except for MBD2—at methylated sites. Notably, sites bound
by MBD2 in a methylation-independent manner are similarly
bound by MBD3 and represent predominantly tissue-specific
regulatory elements with dynamic DNA methylation changes
during lineage commitment. This finding is in line with a
regulatory role of the MBD3-NuRD complex in modulating
transcriptional activity, rather than repressing silent genes
(Reynolds et al., 2012), further suggesting similar functions for490 Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc.MBD2-NuRD. Importantly, the same sites are still bound by
MBD2 and MBD3 in the absence of 5-methylcytosine and 5-hy-
droxymethylcytosine, arguing against a role for these cytosine
modifications in recruiting the NuRD complex to genomic targets
in vivo (Ng et al., 1999; Zhang et al., 1999; Yildirim et al., 2011).
This finding challenges the concept that the repressive effect
of DNA methylation is mediated by the recruitment of chro-
matin-modifying proteins to methylated DNA by MBD domain
proteins.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
Wild-type embryonic stem cells HA36CB1, derived from mixed 129-C57Bl/6
background blastocysts and TKO-133 modified from DnmtTKO (Tsumura
et al., 2006), were cultivated on feeder cells or 0.2% gelatine coated dishes.
ES cell growth medium consisted of DMEM (Invitrogen) supplemented
with 15% fetal calf serum (Invitrogen), 13 nonessential amino acids (Invitro-
gen), 1 mM L-glutamine, LIF, and 0.001% b-mercaptoethanol. Differentiation
was performed as previously described (Bibel et al., 2007). Information on
the generation of Bir-A-positive cell lines is in the Extended Experimental
Procedures.
Generation of Biotag-MBD Protein Library and Cell Lines
All methyl-CpG-binding protein cDNAs were amplified from a random hexam-
ere reverse transcription cDNA library (Superscript III, Invitrogen) generated
from TRIzol total RNA extracts. MBD protein cDNAs were then cloned into
pL1-CAGGS-bio-MCS-polyA-1L, pL1-CMV-bio-MCS-polyA-1L, or pCAGGS-
bio-MCS-IRES-BlasticidinR-polyA. Single amino acid mutations were intro-
duced via quick-change PCR, and domain deletions were generated by
PCR or Gibson assembly. Primers used for generating the MBD protein library
and detailed cloning strategies are available upon request.
Biotin-tagged MBD protein HA36CB1 ES cell lines were obtained by recom-
binase-mediated cassette exchange (RMCE) as previously described (Lienert
et al., 2011). Resistant clones were initially tested for successful insertions by
PCR and Southern blot analysis. Immunoblot and immunofluorescence
confirmed homogenous expression of biotin-tagged MBD proteins. TKO 113
clones were electroporated with linearized pCAGGS-bio-cMBD-IRES-Blasti-
cidinR-polyA constructs and selected on Blasticidin for 10 days. Resistant
clones were screened for stable and homogenous biotag-MBD protein
expression by immunoblot and immunofluorescence analysis.
Biotin-Streptavidin and Antibody-Based Protein
Immunoprecipitation Analysis
Nuclear proteins from ESC, progenitors, or neurons were enriched by nuclear
fractionation. Streptavidin-biotin pull-downs were performed with preblocked
(0.1% cold fish skin gelatine) 30 ml Streptavidin-M280magnetic beads (Invitro-
gen) in HENG buffer, 150 mM NaCl, at 4C overnight. Streptavidin magnetic
beads were washed three times each 10 min with HENG buffer, 250 mM
NaCl, 0.3% NP40, 1 mM DTT, and protease inhibitors at 4C. Antibody
pull-downs were performed as above with slight modifications, and lysates
were precleared with protein A or G agarose beads (depending on isotype)
for 1 hr, rotating at 4C. Precleared lysates were incubated overnight
with antibodies against NuRD or Sin3A components and subsequently with
protein A or G agarose beads for 3 hr. Washing was performed as above
with centrifugation between steps. IPs were resuspended in Laemmli
buffer prior to SDS-PAGE and western blotting to PVDF membranes.
Membranes were blocked with 5% milk or 5% BSA for detection with anti-
bodies or Streptavidin-HRP, respectively. Antibodies and concentrations
used are listed in Table S3.
Biotin-Streptavidin Chromatin Immunoprecipitation
For cross-linking and chromatin extraction, cells were fixed for 10min with 1%
formaldehyde at room temperature and incubated for 10 min on ice in pres-
ence of 1.2 M glycine. Cells were harvested and treated for 10 min with
10mMEDTA, 10mM TRIS, 0.5 mMEGTA, and 0.25% Triton X-100 and 10min
in 1mMEDTA, 10mMTRIS, 0.5mMEGTA, and 200mMNaCl with subsequent
lysis in 50 mM HEPES, 1 mM EDTA, 1% Triton X-100, 0.1% deoxycholate,
0.1% SDS, and 150 mM NaCl for 2 hr on ice. Crosslinked chromatin was sub-
jected to sonication in a Bioruptor instrument (Diagenode). Streptavdin-M280
magnetic beads were blocked for 1 hr with 0.1% cold fish skin gelatin and 100
ng tRNA. 150–250 mg chromatin were precleared with protein A Dynabeads
and incubated with 40 ml blocked streptavidin-M280 magnetic beads over-
night at 4C. Beads were washed with two rounds of 2% SDS, 13 high-salt
buffer, 13 LiCl buffer, and two rounds of TE. Beads were treated with RNaseA
for 30 min at 37C and proteinase K for 3 hr at 65C and were then decros-
slinked overnight at 55C. DNAwas purified with phenol-chloroform extraction
and ethanol precipitation.
Library Preparation and High-Throughput Sequencing and Data
Analysis
Sequencing libraries were prepared using custom inline bar-coded adapters
(Lefranc¸ois et al., 2009; Table S4) following standard Illumina library prepara-
tion kits and protocols. Four samples with different barcodes were mixed at
equal molar ratios per pool. Sequencing of library pools was performed on
Illumina HiSeq 2000 machines according to Illumina standards. Bar-coded
reads were demultiplexed into individual samples (FASTX, http://hannonlab.
cshl.edu/fastx_toolkit/), filtered for low-quality reads and adaptor sequences,
and mapped to the mouse genome (version mm9) using the BOWTIE
algorithm (http://bowtie-bio.sourceforge.net/) allowing for two mismatches
and mapping up to 100 different genomic sites per read. For downstream
analysis, we converted the reads into the genomic ranges format (Genomi-
cRanges, R), filtered out all reads that mapped to more than one genomic
site, and shifted the read position to account for sonication fragment length
using the Chip-seq package in R. Finally, we obtained a minimum of 15 million
uniquely mapped reads per sample, with sequencing depth for wild-type
MBD proteins exceeding 30 million unique reads. Replicates were pooled
for subsequent analysis. DNA methylation reads from bisulphite sequencing
were processed as described (Stadler et al., 2011).
Detailed information on data processing, genomic coordinates, and data
analysis are in the Extended Experimental Procedures.
ACCESSION NUMBERS
All high-throughput sequencing data generated in this study were deposited at
NCBI’s Gene Expression Omnibus and are accessible through GEO
Series accession number GSE39610. Additional data sets used in this study
are listed in Table S5.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and five tables and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2013.03.011.
ACKNOWLEDGMENTS
We are grateful to Sophie Dessus-Babus, Tim Roloff (FMI), Ina Nissen, and
Christian Beisel (ETH BSSE) for processing deep sequencing samples. We
thank Christiane Wirbelauer and Leslie Hoerner for technical assistance and
Michael Stadler, Dimos Gaidatzis, and Lukas Burger for bioinformatic advice
and providing tools to process and analyze deep sequencing data. We thank
Masaki Okano (RIKEN) for providing TKO cells; FMI facilities for technical sup-
port; and Nicolas Thoma¨ (FMI), Matthew Lorincz (UBC Vancouver), Oliver Bell
(HHMI/Stanford University), and members of the Schu¨beler lab for advice and
critical comments on themanuscript. T.B. is supported by an EMBO long-term
postdoctoral fellowship. Research in the laboratory of D.S. is supported by the
Novartis Research Foundation, the European Union (NoE ‘‘EpiGeneSys’’ FP7-
HEALTH-2010-257082 and the ‘‘Blueprint’’ consortium FP7-282510), the
European Research Council (EpiGePlas), the SNF Sinergia program, and the
Swiss initiative in Systems Biology (RTD Cell Plasticity).Received: September 18, 2012
Revised: January 31, 2013
Accepted: March 6, 2013
Published: March 28, 2013
REFERENCES
Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U., and Zoghbi,
H.Y. (1999). Rett syndrome is caused bymutations in X-linkedMECP2, encod-
ing methyl-CpG-binding protein 2. Nat. Genet. 23, 185–188.
Bibel, M., Richter, J., Lacroix, E., and Barde, Y.-A. (2007). Generation of a
defined and uniform population of CNS progenitors and neurons from mouse
embryonic stem cells. Nat. Protoc. 2, 1034–1043.
Boeke, J., Ammerpohl, O., Kegel, S., Moehren, U., and Renkawitz, R. (2000).
The minimal repression domain of MBD2b overlaps with the methyl-CpG-
binding domain and binds directly to Sin3A. J. Biol. Chem. 275, 34963–34967.
Boyes, J., and Bird, A. (1992). Repression of genes by DNA methylation
depends on CpG density and promoter strength: evidence for involvement
of a methyl-CpG binding protein. EMBO J. 11, 327–333.
Chahrour, M., Jung, S.Y., Shaw, C., Zhou, X., Wong, S.T.C., Qin, J., and
Zoghbi, H.Y. (2008). MeCP2, a key contributor to neurological disease,
activates and represses transcription. Science 320, 1224–1229.
Cokus, S.J., Feng, S., Zhang, X., Chen, Z., Merriman, B., Haudenschild, C.D.,
Pradhan, S., Nelson, S.F., Pellegrini, M., and Jacobsen, S.E. (2008). Shotgun
bisulphite sequencing of the Arabidopsis genome reveals DNA methylation
patterning. Nature 452, 215–219.
Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A., Doyle, F.,
Epstein, C.B., Frietze, S., Harrow, J., Kaul, R., et al.; ENCODE Project
Consortium. (2012). An integrated encyclopedia of DNA elements in the human
genome. Nature 489, 57–74.
Frauer, C., Rottach, A., Meilinger, D., Bultmann, S., Fellinger, K., Haseno¨der,
S., Wang, M., Qin, W., So¨ding, J., Spada, F., and Leonhardt, H. (2011).
Different binding properties and function of CXXC zinc finger domains in
Dnmt1 and Tet1. PLoS ONE 6, e16627.
Free, A.,Wakefield, R.I., Smith, B.O., Dryden, D.T., Barlow, P.N., and Bird, A.P.
(2001). DNA recognition by the methyl-CpG binding domain of MeCP2. J. Biol.
Chem. 276, 3353–3360.
Hashimoto, H., Liu, Y., Upadhyay, A.K., Chang, Y., Howerton, S.B., Vertino,
P.M., Zhang, X., and Cheng, X. (2012). Recognition and potential mechanisms
for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res.
40, 4841–4849.
Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp,
L.F., Ye, Z., Lee, L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifi-
cations at human enhancers reflect global cell-type-specific gene expression.
Nature 459, 108–112.
Hendrich, B., and Bird, A. (1998). Identification and characterization of a family
of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18, 6538–6547.
Hendrich, B., Guy, J., Ramsahoye, B.,Wilson, V.A., and Bird, A. (2001). Closely
related proteins MBD2 and MBD3 play distinctive but interacting roles in
mouse development. Genes Dev. 15, 710–723.
Jin, S.-G., Kadam, S., and Pfeifer, G.P. (2010). Examination of the specificity
of DNA methylation profiling techniques towards 5-methylcytosine and 5-
hydroxymethylcytosine. Nucleic Acids Res. 38, e125.
Jørgensen, H.F., Ben-Porath, I., and Bird, A.P. (2004). Mbd1 is recruited to
both methylated and nonmethylated CpGs via distinct DNA binding domains.
Mol. Cell. Biol. 24, 3387–3395.
Lefranc¸ois, P., Euskirchen, G.M., Auerbach, R.K., Rozowsky, J., Gibson, T.,
Yellman, C.M., Gerstein, M., and Snyder, M. (2009). Efficient yeast ChIP-Seq
using multiplex short-read DNA sequencing. BMC Genomics 10, 37.
Lewis, J.D., Meehan, R.R., Henzel, W.J., Maurer-Fogy, I., Jeppesen, P., Klein,
F., and Bird, A. (1992). Purification, sequence, and cellular localization of a
novel chromosomal protein that binds to methylated DNA. Cell 69, 905–914.Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc. 491
Lienert, F., Wirbelauer, C., Som, I., Dean, A., Mohn, F., and Schu¨beler, D.
(2011). Identification of genetic elements that autonomously determine DNA
methylation states. Nat. Genet. 43, 1091–1097.
Lister, R., Pelizzola, M., Dowen, R.H., Hawkins, R.D., Hon, G., Tonti-Filippini,
J., Nery, J.R., Lee, L., Ye, Z., Ngo, Q.-M., et al. (2009). Human DNA methyl-
omes at base resolution show widespread epigenomic differences. Nature
462, 315–322.
Martı´n Caballero, I., Hansen, J., Leaford, D., Pollard, S., and Hendrich, B.D.
(2009). The methyl-CpG binding proteins Mecp2, Mbd2 and Kaiso are
dispensable for mouse embryogenesis, but play a redundant function in neural
differentiation. PLoS ONE 4, e4315.
Meehan, R.R., Lewis, J.D., McKay, S., Kleiner, E.L., and Bird, A.P. (1989).
Identification of a mammalian protein that binds specifically to DNA containing
methylated CpGs. Cell 58, 499–507.
Melle´n, M., Ayata, P., Dewell, S., Kriaucionis, S., and Heintz, N. (2012). MeCP2
binds to 5hmC enriched within active genes and accessible chromatin in the
nervous system. Cell 151, 1417–1430.
Mohn, F., Weber, M., Rebhan, M., Roloff, T.C., Richter, J., Stadler, M.B., Bibel,
M., and Schu¨beler, D. (2008). Lineage-specific polycomb targets and de novo
DNA methylation define restriction and potential of neuronal progenitors. Mol.
Cell 30, 755–766.
Nan, X., Campoy, F.J., and Bird, A. (1997). MeCP2 is a transcriptional
repressor with abundant binding sites in genomic chromatin. Cell 88, 471–481.
Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N.,
and Bird, A. (1998). Transcriptional repression by themethyl-CpG-binding pro-
tein MeCP2 involves a histone deacetylase complex. Nature 393, 386–389.
Ng, H.H., Zhang, Y., Hendrich, B., Johnson, C.A., Turner, B.M., Erdjument-
Bromage, H., Tempst, P., Reinberg, D., and Bird, A. (1999). MBD2 is a tran-
scriptional repressor belonging to the MeCP1 histone deacetylase complex.
Nat. Genet. 23, 58–61.
Ohki, I., Shimotake, N., Fujita, N., Jee, J., Ikegami, T., Nakao, M., and Shira-
kawa, M. (2001). Solution structure of the methyl-CpG binding domain of
human MBD1 in complex with methylated DNA. Cell 105, 487–497.
Pastor, W.A., Pape, U.J., Huang, Y., Henderson, H.R., Lister, R., Ko, M.,
McLoughlin, E.M., Brudno, Y., Mahapatra, S., Kapranov, P., et al. (2011).
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells.
Nature 473, 394–397.
Reynolds, N., Latos, P., Hynes-Allen, A., Loos, R., Leaford, D., O’Shaugh-
nessy, A., Mosaku, O., Signolet, J., Brennecke, P., Kalkan, T., et al. (2012).
NuRD suppresses pluripotency gene expression to promote transcriptional
heterogeneity and lineage commitment. Cell Stem Cell 10, 583–594.
Saito, M., and Ishikawa, F. (2002). ThemCpG-binding domain of humanMBD3
does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and
MTA2. J. Biol. Chem. 277, 35434–35439.
Sarraf, S.A., and Stancheva, I. (2004). Methyl-CpG binding protein MBD1
couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication
and chromatin assembly. Mol. Cell 15, 595–605.492 Cell 153, 480–492, April 11, 2013 ª2013 Elsevier Inc.Scarsdale, J.N., Webb, H.D., Ginder, G.D., and Williams, D.C., Jr. (2011).
Solution structure and dynamic analysis of chicken MBD2 methyl binding
domain bound to a target-methylated DNA sequence. Nucleic Acids Res.
39, 6741–6752.
Schmiedeberg, L., Skene, P., Deaton, A., and Bird, A. (2009). A temporal
threshold for formaldehyde crosslinking and fixation. PLoS ONE 4, e4636.
Skene, P.J., Illingworth, R.S., Webb, S., Kerr, A.R.W., James, K.D., Turner,
D.J., Andrews, R., and Bird, A.P. (2010). Neuronal MeCP2 is expressed at
near histone-octamer levels and globally alters the chromatin state. Mol. Cell
37, 457–468.
Spruijt, C.G., Gnerlich, F., Smits, A.H., Pfaffeneder, T., Jansen, P.W., Bauer,
C., Mu¨nzel, M.,Wagner, M., Mu¨ller, M., Khan, F., et al. (2013). Dynamic readers
for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152, 1146–
1159.
Stadler, M.B., Murr, R., Burger, L., Ivanek, R., Lienert, F., Scho¨ler, A., van
Nimwegen, E., Wirbelauer, C., Oakeley, E.J., Gaidatzis, D., et al. (2011).
DNA-binding factors shape the mouse methylome at distal regulatory regions.
Nature 480, 490–495.
Tsumura, A., Hayakawa, T., Kumaki, Y., Takebayashi, S.-I., Sakaue, M.,
Matsuoka, C., Shimotohno, K., Ishikawa, F., Li, E., Ueda, H.R., et al. (2006).
Maintenance of self-renewal ability of mouse embryonic stem cells in the
absence of DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b. Genes
Cells 11, 805–814.
Tudor, M., Akbarian, S., Chen, R.Z., and Jaenisch, R. (2002). Transcriptional
profiling of a mouse model for Rett syndrome reveals subtle transcriptional
changes in the brain. Proc. Natl. Acad. Sci. USA 99, 15536–15541.
Williams, K., Christensen, J., Pedersen, M.T., Johansen, J.V., Cloos, P.A.C.,
Rappsilber, J., and Helin, K. (2011). TET1 and hydroxymethylcytosine in
transcription and DNA methylation fidelity. Nature 473, 343–348.
Yasui, D.H., Peddada, S., Bieda, M.C., Vallero, R.O., Hogart, A., Nagarajan,
R.P., Thatcher, K.N., Farnham, P.J., and Lasalle, J.M. (2007). Integrated
epigenomic analyses of neuronal MeCP2 reveal a role for long-range interac-
tion with active genes. Proc. Natl. Acad. Sci. USA 104, 19416–19421.
Yildirim, O., Li, R., Hung, J.-H., Chen, P.B., Dong, X., Ee, L.-S., Weng, Z.,
Rando, O.J., and Fazzio, T.G. (2011). Mbd3/NURD complex regulates expres-
sion of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell
147, 1498–1510.
Young, J.I., Hong, E.P., Castle, J.C., Crespo-Barreto, J., Bowman, A.B., Rose,
M.F., Kang, D., Richman, R., Johnson, J.M., Berget, S., and Zoghbi, H.Y.
(2005). Regulation of RNA splicing by the methylation-dependent transcrip-
tional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. USA
102, 17551–17558.
Zhang, Y., Ng, H.H., Erdjument-Bromage, H., Tempst, P., Bird, A., and Rein-
berg, D. (1999). Analysis of the NuRD subunits reveals a histone deacetylase
core complex and a connection with DNA methylation. Genes Dev. 13,
1924–1935.
